X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

November 18, 2019

Ready Pack™ Sterile Component Solutions for Compounding Pharmacy

The FDA recognizes that compounded drugs serve an important role for patients whose medical needs cannot be met by FDA-approved drugs. However, compounded drugs are not approved by the FDA and therefore, have not been evaluated for safety or efficacy. Poor compounding practices or unsuitable manufacturing conditions can lead to serious adverse effects, or even patient death. Over the past few years, the FDA has taken significant steps to modernize and clarify policies related to the quality of compounding in an effort to ensure continued access to compounded drugs, while also protecting patients from the risks of contaminated or otherwise harmful products<sup>1</sup>. FDA Draft Guidances<sup>2, 3</sup> help to clarify applicable regulatory requirements and specifically address the use and handling of container closure systems.
Amy Kim

Amy Kim,

Sr, Specialist, Scientific Communications

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Ready Pack System

    March 12, 2019

    Molecule to Market – Simplify the Journey™ for New Drug Products

    Cathy Chhour

    Cathy Chhour

    Sr. Technical Account Specialist, TCS

    Various input outline for drug product and user needs

    February 18, 2019

    How to Optimize Delivery for Drugs Delivered via PFS and Auto-Injector

    Royce Brockett

    Royce Brockett

    Director, Product Management, PFS

    Lyophilization Table

    January 31, 2019

    Lyophilized Drug Products – Selecting the Right Components

    Daria Miller

    Daria Miller

    Sr. Technical Account Specialist, TCS

    Load more